Precursor Cell Lymphoblastic Leukemia-Lymphoma Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Precursor Cell Lymphoblastic Leukemia-Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

SarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaNeurofibroma, Plexiform+1 more
National Cancer Institute (NCI)54 enrolled1 locationNCT02390752
Recruiting
Phase 1

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Precursor Cell Lymphoblastic Leukemia-LymphomaLymphomas Non-Hodgkin's B-Cell
Kite, A Gilead Company34 enrolled3 locationsNCT06539338
Recruiting
Early Phase 1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Myelodysplastic Syndromes (MDS)Precursor Cell Lymphoblastic Leukemia-LymphomaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic18 enrolled1 locationNCT06765876
Recruiting
Phase 2

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology & Blood Diseases Hospital, China53 enrolled1 locationNCT06387121
Recruiting
Phase 1

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Instituto de Investigación Hospital Universitario La Paz10 enrolled1 locationNCT06709469
Recruiting
Phase 2

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology & Blood Diseases Hospital, China100 enrolled1 locationNCT05660473
Recruiting

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma

LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaDrug-Induced Diabetes Mellitus+1 more
Aarhus University Hospital100 enrolled1 locationNCT05873322
Recruiting
Not Applicable

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Precursor Cell Lymphoblastic Leukemia-Lymphoma
National Research Center for Hematology, Russia200 enrolled1 locationNCT06237192